No Data
No Data
PTC Therapeutics Is Maintained at Overweight by JP Morgan
PTC Therapeutics Is Maintained at Overweight by JP Morgan
J.P. Morgan Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $53
J.P. Morgan analyst Eric Joseph maintains $PTC Therapeutics(PTCT.US)$ with a buy rating, and adjusts the target price from $43 to $53.According to TipRanks data, the analyst has a success rate of 50.6
Express News | PCT Therapeutics Shares Are Trading Lower. The Company Announced Interim Results From the Phase 2 PIVOT-HD Study of PTC518 in Huntington's Disease Patients
PTC Therapeutics Says FDA Lifts Clinical Hold On Investigational Study In Patients With Rare Weak Nerve Cell Disorder
Thursday, PTC Therapeutics Inc (NASDAQ:PTCT) shared interim results from the Phase 2 PIVOT-HD study of PTC518 in Huntington's disease (HD) patients.HD is an inherited condition in which nerve cells in
Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday
Health care stocks were lower pre-bell Thursday as the Health Care Select Sector SPDR Fund (XLV) was down 0.3% and iShares Biotechnology ETF (IBB) was recently declining by 0.3%. Jazz Pharmaceuticals
PTC Therapeutics Reports Favorable Interim Results in Huntington's Disease Study; US FDA Lifts Clinical Hold
PTC Therapeutics (PTCT) said Thursday that the US Food and Drug Administration has lifted the partial clinical hold on its PTC518 program following favorable interim results from the phase 2 PIVOT-HD
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.